Celgene Co. (CELG) Shares Bought by HCR Wealth Advisors

HCR Wealth Advisors lifted its position in Celgene Co. (NASDAQ:CELG) by 7.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,949 shares of the biopharmaceutical company?s stock after purchasing an additional 824 shares during the quarter. HCR Wealth Advisors? holdings in Celgene were worth $960,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Edgewood Management LLC lifted its position in Celgene by 16.2% during the 2nd quarter. Edgewood Management LLC now owns 13,924,544 shares of the biopharmaceutical company?s stock worth $1,105,887,000 after acquiring an additional 1,943,607 shares during the period. Jennison Associates LLC lifted its position in Celgene by 50.2% during the 3rd quarter. Jennison Associates LLC now owns 8,228,124 shares of the biopharmaceutical company?s stock worth $736,335,000 after acquiring an additional 2,748,302 shares during the period. FMR LLC lifted its position in Celgene by 14.8% during the 2nd quarter. FMR LLC now owns 8,160,001 shares of the biopharmaceutical company?s stock worth $648,067,000 after acquiring an additional 1,051,528 shares during the period. Alliancebernstein L.P. lifted its position in Celgene by 5.8% during the 3rd quarter. Alliancebernstein L.P. now owns 4,197,036 shares of the biopharmaceutical company?s stock worth $375,593,000 after acquiring an additional 231,231 shares during the period. Finally, Renaissance Technologies LLC lifted its position in Celgene by 60.6% during the 2nd quarter. Renaissance Technologies LLC now owns 4,129,438 shares of the biopharmaceutical company?s stock worth $327,960,000 after acquiring an additional 1,558,600 shares during the period. 73.87% of the stock is owned by hedge funds and other institutional investors.

Celgene stock?opened at $69.65 on Monday. The company has a quick ratio of 1.99, a current ratio of 2.13 and a debt-to-equity ratio of 4.06. The firm has a market cap of $48.70 billion, a price-to-earnings ratio of 10.18, a P/E/G ratio of 0.43 and a beta of 1.53. Celgene Co. has a fifty-two week low of $68.91 and a fifty-two week high of $110.81.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.02 by $0.27. The company had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. On average, research analysts anticipate that Celgene Co. will post 7.45 EPS for the current year.

Several research firms have recently commented on CELG. UBS Group set a $94.00 price target on Celgene and gave the company a ?buy? rating in a report on Saturday, October 27th. BidaskClub cut Celgene from a ?buy? rating to a ?hold? rating in a report on Thursday, September 13th. Mizuho reissued a ?buy? rating and issued a $129.00 price target on shares of Celgene in a report on Tuesday, July 31st.?Zacks Investment Research?raised Celgene from a ?sell? rating to a ?strong-buy? rating and set a $102.00 price target for the company in a report on Wednesday, August 1st. Finally, SunTrust Banks reissued a ?hold? rating and issued a $101.00 price target on shares of Celgene in a report on Friday, July 27th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company?s stock. The stock currently has a consensus rating of ?Buy? and a consensus target price of $116.99.

About Celgene

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.